開立醫療(300633.SZ):擬出資不超6億元在武漢投建高端醫療器械研發生產基地
格隆匯 9 月 30日丨開立醫療(300633.SZ)公佈,公司於2020年9月30日召開了第二屆董事會第十六次會議,審議通過了《關於公司擬在武漢投資建設高端醫療器械研發生產基地的議案》,同意公司在武漢東湖新技術開發區(以下簡稱“東湖高新區”)投資建設高端醫療器械研發生產基地,項目投資總額不超過6億元人民幣,基地主要建設內容為:開立華中區醫療器械高端研發基地,微導管超聲、超聲內窺鏡等高端醫療器械產品生產線,內窺鏡全球維修服務中心及其相應配套設施。
本事項尚需提交公司股東大會審議,本次對外投資事宜不構成關聯交易,亦不構成《上市公司重大資產重組管理辦法》規定的重大資產重組。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.